8-K: Fulgent Genetics Reports Q3 2024 Results: Core Revenue Up 9%, Improves Full Year EPS Guidance

Fulgent Genetics announced a 9% year-over-year increase in core revenue to $71.7 million for the third quarter of 2024 and improved its full-year earnings per share guidance.

Summary

• Fulgent Genetics reported a total revenue of $71.7 million for the third quarter of 2024.
• Core revenue, which excludes COVID-19 testing revenue, also reached $71.7 million, representing a 9% increase year-over-year.
• The company experienced a GAAP loss of $14.6 million, or ($0.48) per share, but a non-GAAP income of $9.4 million, or $0.31 per share.
• Adjusted EBITDA income was $0.4 million for the quarter.
• As of September 30, 2024, Fulgent had $815.4 million in cash, cash equivalents, restricted cash, and investments in marketable securities.
• For the full year 2024, Fulgent anticipates core revenue of approximately $280 million.
• The company has improved its full-year GAAP loss per share guidance from approximately ($1.95) to approximately ($1.70).
• Non-GAAP loss per share guidance has also improved from approximately ($0.30) to approximately $0.33 income per share.
• Fulgent expects to have approximately $800 million in cash, cash equivalents, and investments in marketable securities by December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the core revenue growth, improved earnings guidance, and progress in therapeutic development. However, the GAAP loss and the potential for increased cash expenditures temper the overall optimism.

Positives

• Core revenue grew by 9% year-over-year, indicating strong performance in the company's primary business.
• Non-GAAP income and earnings per share were positive, showing profitability when excluding certain non-cash items.
• The company has a strong cash position with over $800 million in cash and investments.
• Full-year guidance for core revenue is maintained, and earnings per share guidance has been improved.
• The Laboratory Services business is showing positive momentum with sequential growth.
• The therapeutic development business is progressing with encouraging preliminary results from clinical trials.

Negatives

• The company reported a GAAP loss of $14.6 million, or ($0.48) per share, for the third quarter.
• Adjusted EBITDA was only $0.4 million, indicating a relatively low level of profitability.
• The company's cash position is expected to decrease by the end of the year.

Risks

• The company's cash expenditures may be higher or lower than currently estimated due to various factors, including stock repurchases.
• The market potential for the company's tests and the rate of market adoption are subject to uncertainty.
• The company's ability to maintain turnaround times and keep pace with rapidly changing technology is a risk.
• The company's success in obtaining coverage and reimbursement from third-party payors is not guaranteed.
• The company's development efforts, including clinical trials, are subject to risks and uncertainties.
• The company's compliance with evolving laws and regulations is a risk.
• The company's ability to protect its proprietary technology and intellectual property is a risk.

Future Outlook

Fulgent expects core revenue of approximately $280 million for the full year 2024, with improved GAAP loss per share of approximately ($1.70) and non-GAAP income per share of approximately $0.33. The company also anticipates having approximately $800 million in cash, cash equivalents, and investments by the end of 2024.

Management Comments

• Ming Hsieh, Chairperson of the Board of Directors and Chief Executive Officer, said, 'We continue to see good momentum in our business, with Laboratory Services fueling our initiatives and exhibiting sequential growth in all three areas of our Laboratory Services business for the quarter.'
• Paul Kim, Chief Financial Officer, said, 'We are pleased with our financial performance in the third quarter and our trajectory for the remainder of 2024, as we continue to grow core revenue and improve operations.'

Industry Context

This announcement reflects the ongoing shift in the diagnostics industry towards precision medicine and the integration of therapeutic development. Fulgent's focus on both diagnostics and therapeutics positions it to capitalize on the growing demand for personalized healthcare solutions. The company's expansion into oncology and its development of a nano-drug delivery platform are aligned with industry trends towards more targeted and effective cancer treatments.

Comparison to Industry Standards

• Fulgent's 9% core revenue growth is a positive sign, but it is important to compare this to other genetic testing companies such as Exact Sciences (EXAS) or Invitae (NVTA), which have seen varying growth rates in recent quarters.
• The company's GAAP loss of $14.6 million is not unusual for a company investing in R&D, but it is important to monitor its progress towards profitability compared to peers like Myriad Genetics (MYGN).
• Fulgent's cash position of $815.4 million is strong compared to many smaller biotech companies, but it is important to assess how this capital is being deployed compared to companies like Illumina (ILMN) which have significant R&D budgets.
• The company's focus on a nano-drug delivery platform is a unique approach compared to companies focused solely on diagnostics, and its success will depend on the clinical trial results and regulatory approvals compared to other companies in the oncology therapeutics space such as Amgen (AMGN) or Bristol Myers Squibb (BMY).

Stakeholder Impact

• Shareholders will be impacted by the improved earnings guidance and the company's progress in both diagnostics and therapeutics.
• Employees may be impacted by the company's growth and expansion.
• Customers will benefit from the company's continued development of new diagnostic and therapeutic solutions.
• Suppliers may be impacted by the company's growth and increased demand for its products and services.
• Creditors will be impacted by the company's financial performance and cash position.

Next Steps

• The company will continue to advance its Phase 2 clinical trial of FID-007 in Head and Neck Cancer.
• The company will move FID-022 through preclinical studies toward an Investigational New Drug (IND) application.
• The company will host a conference call to discuss the third quarter results.
• The company will continue to grow its diagnostic and therapeutic opportunities through organic investments and M&A.

Key Dates

Keywords

genetics, laboratory services, therapeutics, cancer, diagnostics, revenue, EBITDA, clinical trials, non-GAAP, precision medicine